Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Med Microbiol Immunol. 2015 Apr 1;204(3):439–448. doi: 10.1007/s00430-015-0410-5

Figure 6. Role of HSV2 ICP10 in necroptosis of mice cells.

Figure 6

A. Viability of 3T3-SA-EV or 3T3-SA-ICP10 cell lines treated for 18h with TNF (T, 25 ng/mL) and/or caspase inhibitor zVAD (V, 25 µM) in the absence or presence of RIP3 kinase inhibitor GSK’872 (5 µM). B. Viability of 3T3-SA-EV or 3T3-SA-ICP10 cell lines infected with MCMV parental K181 or M45mutRHIM virus (MOI=10) for 18h. C. Viability of IFNβ-primed 3T3-SA cells for 24 h following treated with poly(I:C) (25 µg/ml) in the absence or presence of zVAD for 18h. D. Viability of 3T3-SA-EV or 3T3-SA-M45 cells treated for 18 h with T+V or poly(I:C)+V, or infected with M45mutRHIM virus. E. Viability of L929-EV or L929-ICP10 cells treated for 18 h with T and/or V. F. Viability of MEF-EV or MEF-ICP10 cells treated for 18 h with T, V, IAP antagonist BV6 (S; 1 µM) or the indicated combinations. Viability was determined by measuring ATP levels as in Figure 5.